Nordic Nanovector Appoints Eduardo Bravo as Chief Executive Officer
OSLO, 25 June, 2018 -- (Healthcare Sales & Marketing Network) -- Nordic Nanovector ASA (OSE: NANO) announces that Eduardo Bravo has been appointed as its Chief Executive Officer.
Mr. Bravo brings more than 25 years' experience in the biopharmaceutical ... Biopharmaceuticals, Oncology, Personnel Nordic Nanovector, Betalutin, non-Hodgkin's lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Lymphoma | Marketing | Nanotechnology | Non-Hodgkin's Lymphoma | Pharmaceuticals